Background: A pharmacoeconomic analysis of the RISCAVID database aimed at assessing the cost effectiveness of phosphate binders in preventing CV mortality and morbidity over 7 years was performed. Methods: Morbid or fatal events occurring in 750 chronic HD patients were recorded. Statistical analysis evaluated the distribution of variables and the effect of sevelamer on survival. A cost-effectiveness evaluation was performed using a probabilistic model based on a Markov chain. Results: Multivariate analysis showed that treatment with sevelamer was associated with a reduced stroke incidence by 52% (p = 0.04) and reduced levels of C-reactive protein (p < 0.01). Cost-effectiveness evaluation evidenced a 33% decrease in hospital-days for patients treated with sevelamer, with and without comorbidities compared to patients undergoing calcium binders treatment. Conclusion: Treatment with sevelamer was associated with a reduced risk of stroke in HD patients, with a clear saving on disease-related costs for the Italian National Healthcare System.

Keywords:
Sevelamer, Calcium binders, Chronic kidney disease-mineral bone disease syndrome, Stroke, Cardiovascular death, Phosphate, Calcium
1.
Floege J, Kim J, Ireland E, Chazot C, et al: on behalf of the ARO Investigators. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011;26:1948-1955.
2.
Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-2138.
3.
National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-S201.
4.
Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K: Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis 2010;56:842-851.
5.
Alam S, Hussain A, Daiwajna R, Tan J: Clinical efficacy of sevelamer hydrochloride in patients with end-stage renal disease: a retrospective study. Singapore Med J 2013;54:263-266.
6.
Chue CD, Townend JN, Steeds RP, Ferro CJ: Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial. Trials 2001;12:30.
7.
Di Lullo L, Floccari F, Santoboni A, et al: Progression of cardiac valve calcification and decline of renal function in CKD patients. J Nephrol 2013;26:739-744.
8.
Panichi V, Rizza GM, Paoletti S, et al: Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant 2008;23:2337-2343.
9.
Panichi V, Bigazzi R, Paoletti S, et al: Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: results from the RISCAVID study. J Nephrol 2010;23:556-562.
10.
Panichi V, Maggiore U, Taccola D, et al: Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004;19:1154-1160.
11.
Frick KD: Microcosting quantity data collection methods. Med Care 2009;47:S76-S81.
12.
Rost NS, Wolf PA, Kase CS, et al: Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001;32:2575-2579.
13.
Tarkowski E, Rosengren L, Blomstrand C, et al: Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995;26:1393-1398.
14.
Takagi K, Masuda K, Yamazaki M, Kiyohara C, Itoh S, Wasaki M, Inoue H: Metal ion and vitamin adsorption profiles of phosphate binder ion-exchange resins. Clin Nephrol 2010;73:30-35.
15.
Collins AJ, St Peter WL, Dalleska FW, Ebben JP, Ma JZ: Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol 2000;54:334-341.
16.
Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M: Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 2007;22:2867-2878.
17.
Ruggeri M, Cipriani F, Bellasi A, Russo D, Di Iorio B: Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in Italy: a patient-level cost-effectiveness analysis of the INDEPENDENT Study. Blood Purif 2014;37:316-324.
18.
Ruggeri M, Bellasi A, Cipriani F, Molony D, Bell C, Russo D, Di Iorio B: Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study. J Nephrol 2014, Epub ahead of print.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.